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Abstract 25 
Hematopoietic Stem Cells (HSCs) located in adult bone marrow or fetal liver in mammals 26 
produce all cells from the blood system. At the top of the hierarchy are long-term HSCs 27 
endowed with lifelong self-renewal and differentiation properties. These features are 28 
controlled through key microenvironmental cues and regulatory pathways such as Wnt 29 
signaling. We have previously shown that PTK7, a tyrosine kinase receptor involved in 30 
planar cell polarity (PCP), plays a role in epithelial Wnt signaling. However, its function in 31 
hematopoiesis has remained unexplored. Here we show that PTK7 is expressed by 32 
hematopoietic stem and progenitor cells (HSPCs) with the highest protein expression level 33 
found on HSCs. Taking advantage of a Ptk7 deficient mouse strain, we demonstrate that 34 
loss of Ptk7 leads to a diminished pool of HSCs, but does not affect in vitro or in vivo 35 
hematopoietic cell differentiation. This is correlated with increased quiescence and reduced 36 
homing capacities of Ptk7 deficient HSPCs, unravelling novel and unexpected functions for 37 
planar cell polarity pathways in HSC fate.  38 
  39 
40 
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Introduction 41 
Hematopoiesis is a biological process consisting on the production of all blood cell 42 
types from hematopoietic stem cells (HSCs) located in the bone marrow (BM) of adult 43 
mammals. Fetal hematopoiesis occurs in different sites, particularly in the liver, during its 44 
earliest phases. Long term hematopoietic stem cells (LT-HSCs) are characterized by their 45 
capacity to provide lifelong reconstitution of all blood cell lineages after transplantation 46 
into lethally irradiated recipients, whereas short term HSCs (ST-HSCs) do so for only 8-10 47 
weeks. 48 
 In the mouse, LT-HSCs belong to the LSK cell compartment defined by the 49 
Lineage-/low Sca1+c-Kit+ phenotype irrespectively of their fetal liver (FL) or adult bone 50 
marrow (BM) origin. Additional markers known as SLAM (Signal Lymphocytes Activating 51 
Molecules) can further subdivide this compartment (1)(2). Indeed, CD150+CD48- LSK have 52 
been shown to contain around 40% of HSCs with long-term reconstitution potential in BM 53 
as well as in FL (3).  54 
Hematopoiesis is a highly controlled multi-step process that relies on complex 55 
interaction networks involving cell surface receptors, growth factors, and adhesion 56 
molecules expressed by HSCs and their environment (4)(5)(6)(7)(8). Because HSCs 57 
generate mature hematopoietic cells, including immune cells, their replacement must be 58 
adjusted to homeostatic or stress conditions such as infections, inflammation or blood loss, 59 
and their expansion must be controlled to avoid exhaustion. This control is made possible 60 
by the coordinated regulation of quiescence, self-renewal, and differentiation through 61 
appropriate signals delivered by functional BM niches (9). HSCs are retained in these BM 62 
niches by cell surface molecules endowed with adhesive and/or signalling functions 63 
expressed by HSCs. These receptors belong to different protein families: integrins (VLA-4) 64 
(10), Immunoglobulin superfamily (Ig Sf) adhesion molecules (6) (11), G Protein Coupled 65 
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Receptors (CXCR4)(12), or tyrosine kinase receptors (TIE2, c-Kit)(13)(14)(15) interacting 66 
with ligands present within the BM microenvironment (16). Discovery of novel molecules 67 
implicated in this multi-step program is of particular importance to embrace its complexity, 68 
develop new strategies aiming at the regeneration of damaged hematopoietic tissues and to 69 
understand hematopoietic diseases. 70 
PTK7 is a planar cell polarity (PCP) receptor belonging to the Immunoglobulin 71 
Superfamily (Ig Sf) and playing important roles during development (17)(18). PCP is 72 
controlled by a non-canonical Wnt pathway, organizes polarization of many epithelial 73 
tissues and organs within the plane and drives cell migration and cell intercalation of non-74 
epithelial cells such as mesenchymal cells (19)(20). Ptk7 deficient mouse embryos show all 75 
signs of typical PCP defects such as severe tube neural and abdomen closure defect with 76 
secondary development abnormalities (21). PTK7 is a type I protein composed of seven Ig 77 
loops in its extracellular region, a transmembrane domain, an intracellular region with a 78 
tyrosine kinase domain (17)(18)(22)(23). While PTK7 is catalytically inactive, the 79 
cytoplasmic domain containing the tyr sine kinase domain is mandatory for receptor 80 
function in vitro and in vivo (24)(25)(26)(27). Both extracellular and intracellular domains 81 
of PTK7 can be released from the plasma membrane following the sequential cleavage of 82 
the receptor by membrane type 1-matrix metalloproteinase (MT1-MMP)/ADAM-17, and γ-83 
secretase, interfering with its PCP and promigratory activities (24)(28)(29). 84 
We have recently found that PTK7 expression is not restricted to epithelial cells. 85 
Indeed, PTK7 is expressed at the cell surface of human hematopoietic progenitors and acute 86 
myeloid leukemia (AML) patient blast cells. Overexpression of the PCP protein leads to 87 
increased cell survival and cell migration of leukemic cells and confers a poor prognosis to 88 
patients independently of other risk factors (27). Similar conclusions were recently drawn 89 
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from studies done in chronic lymphocytic leukemia in which a set of PCP proteins is 90 
upregulated (30). 91 
Although functions of canonical and non-canonical Wnt pathways have been 92 
extensively studied in hematopoiesis (for review see (31)(32)(33)), the role of PTK7 has 93 
never been explored in this process. In the present study, we have thus addressed the 94 
function of PTK7 in physiological hematopoiesis using a mouse model deficient for ptk7 95 
expression. Using flow cytometry, we first mapped expression of PTK7 on HSCs and 96 
progenitors. As PTK7 deficient mice die perinatally, we then studied function of PTK7 in 97 
fetal hematopoiesis and revealed a decreased number of HSPCs in FL of Ptk7 deficient 98 
mice. Although HSC differentiation was not affected, we found a dramatic decrease in 99 
proliferation and migration properties of Ptk7 deficient HSPCs that reveal novel unexpected 100 
functions for this planar cell polarity molecule.   101 
102 
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Methods 103 
Mice 104 
C57BL/6 and C57BL/6-CD45.1 were purchased from Janvier Laboratory and Charles River 105 
Laboratories, respectively. All mice used for transplantation experiments are 6 to 12 weeks 106 
old. Lethal irradiation was done with an X-ray irradiator (X-RAD® 160 X-Ray, PXi) using 107 
a single dose of 8Gy. 108 
PTK7 gene-trap mice were obtained by injection of gene-trap ES XST087 (Bays Genomics, 109 
USA) in E3.5 blastocyst from C57BL/6 mouse. Chimeric mice were back-crossed with B6 110 
mice for seven generations to obtain homogenous genetic background for experiments. All 111 
mice were housed and maintained under specific pathogen-free condition. E14.5 and 15.5 112 
were used in all FL experiments. All animal experiments were performed in agreement with 113 
the French Guidelines for Animal Handling.  114 
 115 
Genotyping 116 
Genotyping of adult mice and embry s was performed by genomic PCR using the 117 
following pairs of primers: 5’- ACGTCACTGGAGAGGAAGTCCGCAG-3’ and 5’ 118 
GATCGAAGCAGGTCCTGTGGTCCT-3’ for wild type allele and 5’- 119 
TTGTGAAGTGGAGGCTCCGGACC-3’ and 5’- 120 
CGATCTTCCTGAGGCCGATACTGTC-3’ for gene trap insertion allele.  121 
 122 
Flow cytometry and cell sorting 123 
For the analysis of hematopoietic stem/progenitor cells in FLs, FLs were dissected from 124 
E14.5 embryos and single cell suspension was made in phosphate-buffered saline (PBS)-125 
2% Fetal Calf Serum (FCS).  126 
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For analysis of hematopoietic stem/progenitor cells in BM, thymus or blood cells obtained 127 
from adult mice were suspended in PBS-2% FCS. For BM and thymus, cells were filtered 128 
using 70 µm cell strainer (BDFalcon) and lysis of red blood cells was done using ACK lysis 129 
buffer (0.15 M NH4Cl, 10mM KHCO3, 0.1mM Na2EDTA, Life Technology) for 2 min at 130 
room temperature. Cells were spun and resuspended in PBS-2%FCS +/- 0.125mM EDTA 131 
for staining. For blood samples, red blood cell lysis was done after staining using BD FACS 132 
Lysing buffer solution (BD Biosciences) following manufacturer instructions. 133 
For flow cytometry analysis and cell sorting, cells were stained with monoclonal antibodies 134 
purchased from Ebiosciences or Biolegend against the following molecules: B220 (clone 135 
6B2),  CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD11b/Mac-1 (M1/70), CD11c 136 
(N418), CD16/32 (93), CD19 (6D5), CD24 (M1/69), CD34 (RAM34), CD45 (30F11), 137 
CD45.1/Ly5.1 (A20), CD45.2/Ly5.2 (104), CD48 (HM48-1), CD49b (DX5), CD49d (R1-138 
2), CD117/c-Kit (2B8 and/or ACK2), CD135 (A2F10), CD150 (TC15-12F12.2), F4/80 139 
(BM8), Gr1 (RB6-8C5), Sca-1 (D7), Ter-119. Antibody human PTK7 and glycophorin A 140 
(11E4B-7-6) were purchased from Miltenyi biotech and Beckman Coulter, respectively.  141 
 All experiments were done by multicolour parametrics analysis using FITC, PE, APC, PE-142 
Cy7, APC-Cy7, PerCPCy5.5, AlexaFluor700, AlexaFluor594, Pacific blue, PE-Cy5, Q-dot 143 
605 fluorochroms or spectral equivalents. Commercial antibodies were used either directly 144 
conjugated or biotinylated. For mouse PTK7 expression, polyclonal rabbit antibody raised 145 
against recombinant PTK7-Fc was used in the experiments. For detection of interesting 146 
antigen, PE or APC-conjugated goat-anti–rabbit (Jackson Immunoresearch Laboratories) 147 
were used as secondary antibodies. To exclude lineage positive cells, streptavidin 148 
conjugated with Alexa A594 (Invitrogen) or Pacific blue (Ebiosciences) were used. 149 
Irrelevant isotype-matched antibodies were used as controls. Cells were stained 20 minutes 150 
at 4°C and rinsed in PBS-2% FCS solution. Viability marker (vivid dye, Invitrogen) was 151 
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added in last staining in PBS solution. Stained cells were analysed by LSR II SORP (laser 152 
405, 488, 561, and 633; BD Bioscience) or sorted by ARIA III (BD Bioscience). LSK cell 153 
populations were purified by cell sorting using a FACS-ARIA with > 95% purity. Results 154 
were analyzed using BD-DIVA Version 6.1.2 software (BD Biosciences) or FlowJo 155 
Version 7.6.2 (TreeStar) software. 156 
 157 
Homing experiments  158 
E14.5 embryos were sacrificed and were immediately genotyped. FL cells from wild type 159 
or gene trap mice were suspended, counted and stained with cell tracker calcein AM and 160 
calcein red-orange (Invitrogen), respectively, according manufacturer instructions. Cells 161 
were mixed at 1/1 ratio and 4.106 total cells were injected through retro-orbital vein in 162 
previously irradiated (8 Gy) mice. 12h after injection, mice were sacrificed and blood, bone 163 
marrow, spleen, liver and thymus samples were analysed for fluorescents cells. 164 
 165 
Transplantation assays 166 
For LSK sorting, FL cells (CD45.2+) were labelled for lineage positive (lin+) cells with 167 
following biotinylated primary rat antibodies (lineage mix): CD3, CD4, CD8, CD19, B220, 168 
DX5, TER-119, GR-1, CD11c. Lin+ cells were depleted by magnetic separation using anti-169 
rat Ig coated magnetic beads (DynaBeads, Lifetechnology). LinNeg cells were also stained 170 
and sorted by FACS according to the phenotype LinNeg, CD45.2+, Kit+ and Sca-1+. CD45.1 171 
mice were lethally irradiated and grafted with 1000 or 400 CD45.2+ LSK cells through the 172 
retro-orbital vein along with 1.105 total BM recipient cells to allow short term reconstitution 173 
and mice survival. Recipient mice survival was followed and BM engraftment was 174 
examined by monitoring donor (CD45.2+ cells) and host cell (CD45.1+ cells) frequency in 175 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
9 
 
the blood. After lethal irradiation, mice were maintained on water containing neomycin 176 
sulfate 1g/500mL for 2 weeks. 177 
 178 
Serial transplantation assay 179 
Lethally irradiated (8 Gy) mice (C57Bl/6, CD45.1) received 3.106 total fetal liver cells (first 180 
transplantation) or BM total cells (next transplantations). BM engraftment was monitored as 181 
described above. 182 
 183 
Competition assay 184 
Lethally irradiated (8 Gy) mice (C57Bl/6, CD45.1) received 2.106 total FL cells from 185 
CD45.2 PTK7 -/- mutant embryos and 2.106 total FL cells from CD45.1+CD45.2+ PTK7+/+ 186 
embryos, issues from crossing of CD57Bl/6, CD45.1 and CD57Bl/6, CD45.2. Plugs are 187 
obtained the same day. BM engraftment was examined by monitoring frequency of 188 
CD45.2+ cells from PTK7 mutant donors and CD45.1+CD45.2+ cells from wild type donor, 189 
excluding CD45.1+ cells from host cells, in the blood. After lethal irradiation, mice were 190 
maintained on water containing neomycin sulfate 1g/500mL for 2 weeks. 191 
 192 
Cell cycle analysis and apoptosis analysis 193 
FL progenitors were enriched as previously described and stained with cKit–APC-194 
eFluor750, CD150-APC, Sca-1-PerCP-Cy5.5, and CD48-PECy7. The biotin-conjugated 195 
lineage combination was revealed with AlexaFluor 594–streptavidin (Invitrogen). For cell 196 
cycle analysis, after extracellular staining, cells were permeabilized, fixed, and stained with 197 
anti–Ki67-FITC MoAb (BD Biosciences) and DAPI as previously described (34). For 198 
apoptosis analysis, cells were stained with PE-annexine V to evaluate annexine V 199 
externalization (BD biosciences) and DAPI. 200 
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 201 
In vitro methylcellulose assays 202 
For methylcellulose colony assays, FL or BM cells suspensions were prepared in Iscove 203 
modified Dulbecco medium (IMDM) supplemented with 2% FBS. 3.104 cells of FL or 204 
1.105 cells of BM were seeded in Methocult M3434 (containing rmSCF 50 ng/mL, rmIL-3 205 
10ng/mL, rhIL-6 10ng/mL, and EPO 3U/mL) (from Stem Cell Technologies, Grenoble, 206 
France) in 35 mm dishes accordingly to manufacturer’s instructions. All assays were done 207 
in triplicated. Colonies (>30 cells) were counted after 13 days of incubation at 37°C, 5% 208 
CO2 and humidified atmosphere. 209 
 210 
Adhesion assays 211 
MS5 stromal cells were plated on 96-well flat bottom plates, at a concentration of 5.103 212 
cells/well 1 day before the assay. MS5 is a stromal cell line that has been generated by 213 
irradiating adherent cells in long-term BM culture. LinNeg FL cells (5.105) obtained as 214 
previously described were cocultured f r 2 hours with MS5 stromal cells. Plates were 215 
washed 3 times with PBS and adherent cells were removed by strong pipetting in PBS 216 
1.25mM EDTA 2% FCS. The phenotype of adherent cells was determined using anti-217 
CD117, Sca-1, CD150, CD48, and FITC-lineage mix to exclude any residual mature cells 218 
contaminating the LinNeg preparation. Absolute numbers were measured using the HTS 219 
coupled to the BD-LSR2 SORP (BD Bioscience). 220 
 221 
Migration assays 222 
LinNeg FL cells were enriched as previously described and suspended in Iscove modified 223 
Dulbecco medium (IMDM) containing 2% of bovine serum albumine. About 2.105 cells in 224 
75 µl were loaded in 5-μm pore Transwell system (Corning Life Sciences). The lower 225 
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chamber was filled with Serum free Media supplemented with the chemoattracting murine 226 
stromal-derived factor-1 (mSDF-1α, 100 ng/mL, Peprotech). The same number of cells was 227 
plated in distinct wells to be used as control for migration. Plates were then incubated 4 228 
hours at 37°C, 5% CO2. All experiments were performed in duplicates. Cells were also 229 
stained using anti-CD117, Sca-1 and streptavidin coupled to Pacific Blue as described 230 
above. Absolute numbers were measured using the HTS coupled to the BD-LSR2 SORP 231 
(BD Bioscience) and the migration ratio was defined as the number of migrating cells 232 
between migration wells and control wells. 233 
 234 
TF1 cell differentiation 235 
Growth of the human erythroid/macrophage progenitor cell line TF1 is dependent on GM-236 
CSF or IL3 and can be induced to differentiate in the presence of growth factors. TF1 cells 237 
were grown in IMDM medium supplemented with 5 ng/ml GM-CSF and supplemented 238 
with EPO (2 UI/ml) for erythroid differentiation. TF1 cells were infected by viral particles 239 
containing shRNA against PTK7 as previously described (27). A scramble non-targeting 240 
shRNA was used as a control. shRNA efficiency for PTK7 downregulation was controlled 241 
by flow cytometry before and at the end of experiments. TFI cells were then differentiated 242 
in IMDM with 2 IU/ml EPO and without GM-CSF for a total of seven days as previously 243 
described (35). Erythroblastic differentiation was evaluated by glycophorin A expression. 244 
 245 
Statistical analysis 246 
Statistical significance was determined with nonparametric Mann-Withney U test using 247 
Prism Version 5 software (Graphpad Software Inc).  248 
249 
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Results 250 
 251 
PTK7 is expressed on HSCs, myeloid progenitors, lymphoid and thymic progenitors 252 
In a first approach, we studied PTK7 pattern of expression in adult murine hematopoietic 253 
cells. To this end, a rabbit polyclonal antibody generated against the extracellular region of 254 
PTK7 was used. This antibody recognizes mouse PTK7 endogenously expressed on 255 
endothelial and hematopoietic cells by FACS analysis in wild type but not ptk7 deficient 256 
mice (Supplementary Fig. S1). Analysis of PTK7 expression in peripheral blood and in 257 
splenocytes revealed that none of the mature mouse leukocytes subsets (granulocytes, 258 
monocytes, B cells and T cells) expressed PTK7 to detectable level (Fig. 1A and data not 259 
shown). We next analysed PTK7 expression in murine BM hematopoietic progenitors using 260 
multiparametric flow cytometry and gating strategies described in Figure 1B. When LSK 261 
subsets were examined, PTK7 expression was found to be inversely correlated to 262 
differentiation stages with the highest expression on HSCs and multipotent progenitors 263 
(MPP) type 1 HSC-MPP1 (RFI=40), and intermediate expression on MPP2 (RFI=20) and 264 
MPP3-MPP4 (RFI=15) (Fig. 1C). More committed progenitors including common myeloid 265 
progenitors (CMP) and common lymphoid progenitors (CLP) expressed PTK7 at lower 266 
levels while the protein was almost undetectable on the surface of granulocyte-macrophage 267 
progenitor (GMP), and megakaryocyte–erythroid progenitor (MEP) (Fig. 1D). A similar 268 
phenotypic analysis was conducted on differentiating T cells isolated from the thymus.  T 269 
cell progenitors do not express CD4 and CD8 markers and are called double negative (DN) 270 
cells before differentiation into double positive (DP) and single positive (SP) cells. Within 271 
the DN compartment, four thymic progenitor populations can be identified according to 272 
CD44 and CD25 expression from the most immature DN1 to the most mature DN4 subsets. 273 
PTK7 is expressed by the CD44+CD25- (DN1) population and expression is conserved 274 
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during thymic differentiation within the DN2, DN3 and DN4 subpopulations 275 
(Supplementary Fig. S2). PTK7 expression is also detected on DP thymocytes before 276 
becoming progressively lost at the SP stage. Altogether, these phenotypic analyses reveal 277 
that PTK7 expression is inversely correlated to hematopoietic differentiation with the 278 
highest expression found in HSCs. This suggests that PTK7 may play a role at this early 279 
stage of hematopoietic differentiation. 280 
 281 
Ptk7-/- embryos have a quantitative defect of hematopoietic stem cells 282 
We next questioned the function of PTK7 in hematopoiesis. To this end, we generated a 283 
Ptk7 deficient mouse strain using a gene-trapped ES cell available through the International 284 
Gene Trap Consortium. As expected from the previous description of Ptk7 deficient strains, 285 
we observed a perinatal lethality due to profound developmental defects (21). Ptk7 -/- 286 
embryos harbour a severe phenotype with cranial neural tube closure defect, gastroschisis, 287 
kidney and forelimb abnormalities (Fig. 2A, 2B). Considering this dramatic phenotype, it 288 
was impossible to study adult hematopoiesis in these mice and we thus decided to study FL 289 
hematopoiesis. In FL, as well as in the BM, HSCs are comprised within the LSK cell 290 
compartment. Using the same gating strategy as in Figure 1, we analysed the consequences 291 
of PTK7 deficiency in the different LSK cell populations (Fig. 2C). We observed a 25% 292 
decrease of total cellularity at E14.5 in PTK7 deficient FL compared to wild type FL (Fig. 293 
2D). However proportion of leucocytes (e.g. CD45+ cells) is equivalent between deficient 294 
and wild type FL (Fig. 2E) suggesting that the decrease in FL cellularity in Ptk7 -/- embryos 295 
is likely due to a global effect of ptk7 deficiency on FL size. We next examined the 296 
hematopoietic progenitor compartment. A decrease of about 50% of LSK cell frequency 297 
was observed in Ptk7 deficient FL compared to control FL (1.33% Ptk7 +/+ and +/- LSK 298 
cells versus 0.67% Ptk7 -/- LSK cells) (Fig. 2F). In the different LSK cell populations, the 299 
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most affected one was the HSC-MPP1 subset (Fig. 2C and 2G). No significant difference in 300 
the frequency of MMP2 and MPP3-MPP4 subsets was observed in Ptk7 deficient FL 301 
compared to wild type or heterozygous FL. When we examined the absolute number of the 302 
different subsets of hematopoietic progenitors, we noticed that all LSK subsets were 303 
affected by PTK7 deficiency. Indeed, there was a 68% decrease in the LSK cell absolute 304 
number in Ptk7 deficient embryos compared to control embryos (Fig. 2H). The most 305 
dramatic decrease was observed in the HSC compartment. Indeed, there was up to 75% 306 
decrease in HSC number in Ptk7 -/- embryos compared to control one whereas there was 307 
around a 50% decrease in MPP2 and MPP3/4 cell numbers (Fig. 2I) 308 
To assess the frequency of functional HSC in FL, we transplanted 1000 and 400 sorted LSK 309 
cells from Ptk7 +/+ or Ptk7 -/- FL bearing the CD45.2 allele into two groups of lethally 310 
irradiated mice bearing the CD45.1 allele. As expected, all mice included in the group 311 
injected with 1000 LSK cells survived. However, with 400 injected cells, Ptk7 +/+  FL LSK 312 
cells were able to reconstitute recipient mice between 2 and 12 weeks after injection 313 
whereas all mice except one injected with Ptk7 -/- LSK cells died within 6 weeks (Fig. 2J). 314 
We concluded that loss of PTK7 leads to a defect in functional HSC frequency. In vitro 315 
clonogenicity assays confirmed the defect in HSCs and early precursor frequency as we 316 
observed a twofold reduction in colony-forming units starting from 3.104 total FL cells. 317 
(Fig. 2K). 318 
  319 
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PTK7 deficient fetal liver cells are more quiescent than wild type fetal liver cells 320 
To determine if the absence of PTK7 could alter HSC quiescence, we performed cell cycle 321 
phenotypic analysis of LSK FL cells using an antibody directed against Ki-67, a nuclear 322 
marker to measure cell cycle, and DAPI to evaluate the DNA content (Fig. 3A). We found 323 
that a greater proportion of HSCs and early progenitors were in G0 phase in Ptk7 deficient 324 
embryos as compared to control. Indeed, 56% of HSC-MPP1 cells were quiescent in Ptk7 325 
deficient embryos with respect to 46% in control embryos (Fig. 3B). This significant 326 
increase in quiescent cells was maintained throughout hematopoietic differentiation with 327 
respectively 46% versus 39% and 19% versus 14% of the cells in G0 phase at the MMP2 328 
and MPP3-MPP4 stages (Fig. 3B). To exclude that these unbalanced proportion of 329 
quiescent cells was not due to selective apoptosis of cycling Ptk7 deficient cells, we 330 
analyzed the percentage of apoptotic cells in Ptk7 deficient and control FL cells. We did not 331 
observed a difference of apoptosis as measured by Annexin V staining between wild type 332 
and mutant mice in total FL cells and LSK cells (Fig. 3C). These results demonstrate that 333 
PTK7 delivers proliferative signals to HSCs but does not affect HSC survival. 334 
 335 
PTK7 deficient cells are able to reconstitute definitive hematopoiesis in recipient mice 336 
To investigate the functional capacity of Ptk7 deficient HSCs, we generated chimeric mice 337 
using FL cell transplantation. CD45.1 C57Bl/6 mice were lethally irradiated (8 Gy) and 338 
then reconstituted with 3.106 total FL cells from Ptk7 deficient or wild type FL embryos 339 
(CD45.2). Reconstitution and chimerism were followed over time by monitoring the 340 
frequency of donor cells (CD45.2) versus recipient cells (CD45.1) in the peripheral blood 341 
of recipient mice (Fig. 4A). As expected, all recipient mice injected with control FL cells 342 
were reconstituted between 2 and 12 weeks. The same results were obtained with PTK7 343 
deficient FL cells demonstrating that in absence of any competition, Ptk7 deficient HSCs 344 
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are able to reconstitute all mature hematopoietic lineages of lethally irradiated recipients 345 
(Fig. 4B-C). To investigate whether Ptk7 deficiency could lead to more subtle 346 
hematopoietic defects, BM of chimeric mice was analyzed after twelve weeks. No 347 
significant difference was found in frequencies of mature and progenitor cells in the BM 348 
(Fig. 4E-F). In agreement with reconstitution experiments, in vitro differentiation assays 349 
showed that Ptk7 deficient FL cells are able to give rise to all subtypes of colony forming 350 
units in the same proportion than control FL cells (Fig. 4G, left panel and supplementary 351 
Fig.S4). However, we observed fewer colonies generated by Ptk7 deficient HSPC than by 352 
control cells (Fig. 4G, right panel). This is likely due to decreased cell cycle activity of Ptk7 353 
deficient HSPCs while the potential of differentiation is not affected. Since quiescence of 354 
HSCs could be correlated to loss of self-renewal (36), we then tested self-renewal capacities 355 
of Ptk7 deficient HSCs by serial transplantation assays. Recipient CD45.1 mice were 356 
lethally irradiated and reconstituted with CD45.2 donor cells from wild type and mutant 357 
mice. The first injection was performed with 3.106 total FL cells. After 12 weeks, BM cells 358 
were harvested and 3.106 cells were then injected to a second lethally irradiated recipient. 359 
The same protocol was applied for the following transplantations. We monitored chimerism 360 
by flow cytometry analysis and obtained a very good reconstitution with about 95 to 100% 361 
of donor cells in BM for all transplantations (Fig. 4H). We also investigated erythroblastic 362 
reconstitution in mice and did not find any differences in term of hemoglobin level and red 363 
blood cell count (Supplementary Fig. S3A and S3B). In vitro differentiation using TF1 cells 364 
that are able to differentiate in response to EPO did not reveal any difference in the 365 
presence or absence of PTK7 (Supplementary Fig. S3C and S3D). We thus concluded that 366 
PTK7 is not required for hematopoietic differentiation. 367 
To get further insights into PTK7 function in early hematopoiesis, we performed mixed 368 
chimera competition experiments. CD45.1 C57Bl/6 mice were lethally irradiated (8 Gy) 369 
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and then reconstituted with 2.106 total FL cells from Ptk7 deficient (CD45.2) and 2.106 total  370 
FL cells from wild type FL embryos (CD45.2xCD45.1). Reconstitution and chimerism 371 
were followed over time by monitoring the frequency of PTK7-/- cells (CD45.2) and 372 
PTK7+/+ (CD45.2+CD45.1+) versus recipient cells (CD45.1) in the peripheral blood of 373 
recipient mice. We did not observe significant differences at D30 and D60, but observed an 374 
advantage of PTK7-/- cells at long term (>120 jours) (Fig. 5A). Since maintenance of 375 
quiescence is a stem cell property, we tested cell cycle activity of adult HSC in chimeric 376 
mice. Recipient CD45.1 mice were lethally irradiated and reconstituted with CD45.2 donor 377 
cells from wild type and mutant FL mice as previously described. We performed cell cycle 378 
analysis on hematopoietic progenitors more than 6 months post transplantation, when stable 379 
hematopoietic reconstitution is obtained. We confirmed that hematopoietic progenitors 380 
isolated from mice reconstituted with PTK7 deficient cells are more quiescent than wild 381 
type counterparts (Fig. 5B and 5C). Clonogenic experiments confirmed that fewer colonies 382 
are generated by Ptk7 deficient HSPC than by control from chimeric mice (Fig. 5D). These 383 
results suggest that PTK7 is essential for quiescence independently of the 384 
microenvironment. 385 
 386 
Homing and migration defects of Ptk7 deficient cells  387 
Since we have previously described a pro-migratory function of PTK7 in leukemic cell 388 
lines and because increased HSC quiescence may not be the unique cause of the functional 389 
defect of Ptk7-/- HSCs (Fig. 2J), we decided to investigate the role of PTK7 in 390 
hematopoietic homing. FL cells from several Ptk7-/- or Ptk7+/+ embryos were pooled and 391 
stained separately with two different fluorescent trackers. Cells were injected according to a 392 
1/1 ratio and mice were sacrificed 12h after injection. Analysis of homing was performed 393 
by flow cytometry (Fig. 6A-C). Although we observed comparable levels of residual 394 
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circulating cells regardless the PTK7 status in peripheral blood, Ptk7 deficient cells had a 395 
very poor capacity to home to the BM, spleen, liver, and thymus as compared to control 396 
(Fig. 6D). Since homing defect can be explained by loss of cell adhesion to BM stromal 397 
cells and/or by a defect of cell migration toward a chemoattractant, we tested these two 398 
hypotheses. Adhesion of Ptk7 deficient LSK cells on the murine MS5 stromal cell line was 399 
not significantly different from control LSK cells (Fig. 7A). In contrast, we found a 400 
decrease in spontaneous transmigration of Ptk7 deficient FL cells as compared to control 401 
cells in Boyden chamber assay (8% versus 5%, Fig. 7B). No effect was observed with 402 
heterozygous FL cells. We also observed significant differences when the chemokine 403 
SDF1α was used as a chemoattractive molecule. Indeed, whereas 12% of control FL cells 404 
migrated toward SDF1α, only 8% of PTK7 deficient FL cells were able to do so (Fig. 7C). 405 
Without chemoattractant, less than 5% of LSK cells migrated across the transwell 406 
regardless the PTK7 status (Fig. 7D). When SDF1α was used as a chemoattrative molecule, 407 
a twofold decrease in LSK transmigration was observed for Ptk7 deficient cells as 408 
compared to control cells (20% versus 40%, Fig. 7E).  409 
 410 
411 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
19 
 
Discussion 412 
Discovery of novel molecular pathways implicated in HSC maintenance is of 413 
particular interest to develop new strategies aiming at the regeneration of damaged 414 
hematopoietic tissues and to understand hematopoietic diseases such as leukemia. We have 415 
previously identified the cell polarity protein, PTK7, as a novel tyrosine kinase receptor 416 
overexpressed in acute myeloid leukemia (AML). High expression of PTK7 is correlated to 417 
poor prognosis and resistance to chemotherapeutic regimens (27). Recently, another study 418 
revealed that PTK7 is also upregulated in T acute lymphocytic leukemia (T-ALL)(37). In 419 
humans, we and others have evidenced that PTK7 expression is mostly restricted to normal 420 
early progenitors committed to myeloid and T lymphoid lineages. 421 
In the present study, we show that PTK7 expression is similar between mouse and 422 
human systems. PTK7 is absent in mature blood cells and its expression in BM 423 
hematopoietic progenitors is inversely correlated with differentiation. The highest 424 
expression of PTK7 is found in HSC-MPP1 compartment. PTK7 expression is also 425 
conserved between mice and human when the thymic compartment is considered. PTK7 is 426 
easily detectable at the cell surface of CLP and immature DN and DP populations whereas 427 
its expression is lost in single positive CD4 or CD8 lymphocytes. These data correlate with 428 
results from other groups that demonstrated expression of PTK7 by recent thymic emigrants 429 
cells and thymocytes (38)(37). 430 
In order to study the role of PTK7 in hematopoiesis, we generated Ptk7 deficient mice using 431 
available gene-trapped ES cells. Our Ptk7 deficient strain exhibited expected planar cell 432 
polarity defects as compared to another strain of mice issued from the same ES clone (21). 433 
Since these mutant mice cannot reach adulthood, functions of PTK7 were investigated in 434 
FL hematopoietic cells. The major hematopoietic phenotype of Ptk7 deficient mice consists 435 
in increased quiescence of HSPCs and shrinkage of the FL HSPC pool. Although these 436 
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phenotypes may sound logical if one considers that less proliferation produces less cells, 437 
they are difficult to reconciliate with loss of functional reconstitution observed when 438 
recipient mice are engrafted with limited numbers of LSK cells (Fig. 2J). Indeed, PTK7 is 439 
implicated in canonical and non-canonical Wnt pathway (17)(39), which are thought to be 440 
the guardians of the balance between HSC self-renewal and HSC differentiation (32). We 441 
have recently shown that PTK7 plays a role in canonical pathway downstream of Wnt3a 442 
suggesting that deficiency in PTK7 may mirror deficiency in Wnt3a (25). This would be 443 
consistent with results showing that Wnt3a deficiency leads to a reduction in the numbers 444 
of HSPCs in the FL but would not fit with the reduced reconstitution capacity observed in 445 
secondary transplantation assays of Wnt3a deficient cells which is not observed with Ptk7 446 
deficient cells (40). Alternatively, it may well be that PTK7 controls non-canonical pathway 447 
through interaction with Wnt ligands (41) (42). In this way, Wnt5a antagonizes Wnt3a-448 
mediated canonical signaling and increases quiescence of HSCs (43). This occurs through 449 
activation of the small Rho GTPase Cdc42 that increases HSC polarity (44)(45). Such a 450 
function of PTK7 in Wnt5a-mediated non-canonical pathway would fit with the planar cell 451 
polarity function of PTK7 and with altered homing and migrating properties of Ptk7 452 
deficient cells that likely depend on small Rho GTPase activation. Some studies show that 453 
PTK7 regulates the balance between Wnt canonical and non-canonical pathways by 454 
interacting with Dishevelled (26)(46), ROR2 (42)(47), β-catenin (25) and LRP6 (39). We 455 
unsuccessfully tried to identify downstream pathways that could be regulated by Ptk7 in 456 
HSCPs using a candidate gene/protein approach. We also looked at gene expression 457 
differences between Ptk7 knock-out and control hematopoietic cells using unbiased gene 458 
expression profiling. Although we identified differences (data not shown), we could not 459 
find obvious Gene Ontology enrichments or pathways that could be experimentally tested. 460 
Further studies will be needed to unravel how Ptk7 functions in HSPCs. 461 
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 In our model of FL hematopoietic cells, we confirmed the role of PTK7 in cell 462 
migration and found a new role of this protein in cell homing to hematopoietic organs and 463 
in the control of cell proliferation. This observation confirms our previous data obtained 464 
from human leukemia samples (27) can be linked with already described functions of PTK7 465 
in cell migration and in metastatic dissemination. Indeed, we and others have found that 466 
PTK7 expression on various cancer cells is linked with higher metastasis potential 467 
(27)(29)(48)(49). Recently, we also described a poor prognosis of PTK7 expression in 468 
colon cancer cells linked with higher metastatic events (50). In addition, our data show for 469 
the first time that PTK7 is involved in the regulation of hematopoietic and stem and 470 
progenitors cell (HSPC) cycle. Lack of PTK7 expression increases quiescence and 471 
enhances the long term repopulating potential after six months, while a trend toward 472 
decreased chimerism is observed after one or two months. This could reflect the dual 473 
function of PTK7 loss of expression in decreasing short term homing to the bone marrow 474 
and increasing long term establishment of hematopoiesis. Alternatively, it may well be that 475 
homing assay performed with total liver cells reveals a constitutive promigratory function 476 
of PTK7, in contrast to long term engraftment reflecting bone marrow micro-environmental 477 
signaling through PTK7 in HSCs. Similar complex mechanisms of cell cycle regulation and 478 
differential homing of mature cells versus HSPCs homing to the bone marrow have also 479 
been attributed to CXCR4 (51) (52) (53) (54). Whether PTK7 and CXCR4 signaling share 480 
more in common remains to be addressed.  In conclusion, PTK7 overexpression in 481 
immature blasts cells of acute myeloid leukemia has been associated to bad prognosis, early 482 
relapse and chemotherapeutic resistance and a recent study shows that PTK7 can be used as 483 
a stem cell marker of colon cancer stem cells (27)(55). Taken together, all these data form a 484 
set of arguments to involve PTK7 expression in stem cells including cancer stem cells but 485 
also to prove a functional role of PTK7 in stem cell biology. We think that these new data 486 
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on PTK7 involvement on cell cycle are very promising to understand molecular 487 
mechanisms of leukemia/cancer development.  488 
Altogether, our results report a novel unexpected function for the planar cell polarity 489 
molecule PTK7 in the crosstalk between expansion of HSPC compartment and HSPC 490 
migration. This opens new avenue for manipulation of HSC fate using agonists or 491 
antagonists of PTK7.  492 
  493 
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Figure Legends: 694 
 695 
Figure 1: PTK7 expression in wild type bone marrow. (A) Expression of PTK7 in blood 696 
mature cells. Granulocytes are defined as Gr1+CD11b+ cells. Monocytes are defined as 697 
F4/80+ CD11b+CD115+ cells. Lymphocytes are gated using B220, CD19, CD3, CD4 and 698 
CD8 combination. MFI ratios are indicated in dots plots. (B) Strategy of bone marrow 699 
progenitors gating. First panel: Dot plot showing the LSK+ gate within Lin- bone marrow 700 
cells. Second panel: dot plot showing early progenitors gating using SLAM markers. 701 
Hematopoietic stem cells (HSC) are defined as CD150+CD48- cells. More mature 702 
multipotents progenitors (MPP) are defined as CD150+CD48+ (MPP2) and then CD150-703 
CD48+ (MPP3/4). Third panel: dot plot showing engaged progenitors within c-Kit+Sca-1- 704 
Lin- cells. CMP (Common Myeloid Progenitor) is defin d as CD16/32loCD34+. GMP 705 
(Granulocyte-Macrophage Progenitor) is defined as CD34+CD16/32hi. MEP 706 
(Megakaryocyte-Erythroid Progenitor) is defined as CD16/32-CD34-. Fourth panel: Gating 707 
of CLP (Common Lymphoid Progenitor) defined as Lin-IL7Ra+B220-CD24loCD117lo. (C) 708 
Overlays showing expression of PTK7 during differentiation. Black line: PTK7, gray 709 
histogram: isotypic control (pre-immune rabbit antiserum). (D) Quantitative comparison of 710 
expression levels between different progenitor populations: normalization of PTK7 mean of 711 
fluorescence (MFO) with CD117 MFO on LSK subpopulations and progenitors 712 
(CD117+Sca-1- cells). Statistical significance was calculated by nonparametric Mann-713 
Whitney test. All data are shown as the mean ± s.d. *p<0.05. **p<0.01.***p<0.001. 714 
 715 
Figure 2: Phenotype of PTK7 deficient mouse and analysis of fetal liver at E14.5. (A) 716 
PTK7 mutants embryos showing severe planar cell polarity and developmental 717 
abnormalities. (B) Western blot of murine embryonic fibroblasts (MEFs) obtained from a 718 
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litter of our PTK7 gene trapped established mouse line. (C) Dot plots showing LSK gate 719 
within lin- FL cells and SLAM gating within LSK cells. (D) Quantification of total number 720 
fetal liver cells. Data are pooled from 6 litters: Ptk7-/- N=12; Ptk7+/- N=19; Ptk7+/+ N=12 721 
(E) Percentage of CD45+ cells within fetal liver. Data are pooled from 8 litters: Ptk7-/- 722 
N=15; Ptk7+/- N=26; Ptk7 +/+ N=9. (F) Percentage of LSK cells within CD45+ FL cells. (G) 723 
Percentage of LSK subpopulation using SLAM markers. (H) Absolute number of LSK cells 724 
in E14.5 FL. (I) Absolute number of LSK subpopulations using SLAM markers. From (F) 725 
to (I) data are pooled from 10 litters: Ptk7-/- N=19; Ptk7 +/- N=29; Ptk7+/+ N=10. (J) Survival 726 
curves of CD45.1 C57Bl/6 mice engrafted with 400 LSK cells sorted from CD45.2 FL 727 
together with 1.105congenic CD45.1 total bone marrow cells.  Black line: engraftment with 728 
Ptk7+/+ FL cells;  Dashed line: engraftment with Ptk7-/- FL cells. Shown experiment is 729 
representative from 3 separate experiments. N=6 mice per group. (K) Clonogenic capacity 730 
of FL total cells. 3.104 FL cells are seeded in M3434 methylcellulose. Shown experiment is 731 
representative from 3 separate experiments. Ptk7-/- N=6; Ptk7+/+ N=4. All statistical 732 
significance was calculated by nonparametric Mann-Whitney test. All data are shown as the 733 
mean ± s.d. *p<0.05. **p<0.01.***p<0.001. 734 
 735 
Figure 3: Cell cycle and apoptosis analysis of LSK FL cells. (A) Representative dot plots 736 
of DNA content (DAPI) plotted versus Ki-67 nuclear antigen staining on LSK cells. The 737 
cell-cycle phases were defined as G0 (Ki-67- and 2n DNA), G1(Ki-67+ and 2n DNA) and S-738 
G2-M (Ki-67+ and DNA >2n). (B) Percentage of LSK FL cells in cell-cycle phases using 739 
SLAM markers. Data are pooled from 3 separate experiments and embryos (Ptk7-/- N=10; 740 
Ptk7+/+ N=11) from 7 different litters. *p<0.05. **p<0.01. (C) Determination of percentage 741 
of apoptotic cells by staining with annexin V and DAPI. Apoptotic cells were defined as 742 
annexin V+ DAPI−. Results are representative of 8 Ptk7-/- and 6 WT embryos from 5 743 
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different litters. All statistical significance was calculated by nonparametric Mann-Whitney 744 
test. All data are shown as the mean ± s.d. *p<0.05. **p<0.01.***p<0.001. 745 
 746 
Figure 4: Hematological capacity of reconstitution and differentiation. Lethally 747 
irradiated CD45.1 mice (8 Gy) were reconstituted with 3.106 CD45.2 total FL cells isolated 748 
from Ptk+/+ and Ptk-/- embryos. Percentage of each hematological populations from donor 749 
(CD45.2) was monitored by flow cytometry (A). Percentage of matures cells in recipient 750 
blood (B) and in spleen (C). Percentage of BM mature cells (D) and BM progenitors (E) in 751 
recipient mice. (F)  Percentage of LSK cells and LSK subpopulation in recipient BM. White 752 
histograms depict mice reconstituted with Ptk-/- FL. Black histograms depict mice 753 
reconstituted with Ptk+/+ FL. N=6 mice per group. (G) In vitro differentiation capacity of FL 754 
cells. 3.104 FL cells were seeded in methylcellulose. Left panel: Quantification and 755 
characterization of CFU-C. Right panel: Proportion of CFU. (H) Serial transplantation. First 756 
transplantation: Lethally irradiated mice were injected with 3.106 of total E14.5 FL cells 757 
(T1: transplantation 1). Next transplantations were done by injection of 3.106 total bone 758 
marrow cells from previously reconstituted mice in irradiated C57Bl/6 CD45.1 mice (T2 to 759 
T5). Percentage of donor cells (CD45.2) versus recipient cells (CD45.1) was monitored. 760 
Each data represents chimerism of definitive hematopoiesis 3 months after irradiation. Data 761 
are the mean ± s.d. N=6 mice per group. 762 
 763 
Figure 5: Competition experiments and cell cycle in adult mice. (A) 2.106 cells from 764 
Ptk7+/+ (CD45.1xCD45.2) and 2.106 cells from Ptk7-/- (CD45.2) are injected in recipient 765 
(CD45.1) mice. Chimerism is followed in blood samples. Data are representative of 4 766 
independent experiments (N=6 mice per group). (B-D) Recipient CD45.1 mice 767 
reconstituted with CD45.2 donor cells from wild type and mutant FL mice (B) 768 
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Representative dot plots of DNA contents (DAPI) plotted versus Ki-67 nuclear antigen 769 
staining on LSK cells. (C) Percentage of LSK cells in cell cycle phases using SLAM 770 
markers. (D) Clonogenic capacity of BM total cells. 1.105 BM cells are seeded in M3434 771 
methylcellulose. Data are representative of 2 independent experiments (N=6 mice per 772 
group). All statistical significance was calculated by nonparametric Mann-Whitney test. 773 
*p<0.05. **p<0.01.***p<0.001. 774 
 775 
Figure 6: Homing capacities of deficient PTK7 cells. (A) 2.106 of total fetal liver cells 776 
from Ptk7-/- or Ptk7+/+ embryos were stained with cell tracker calcein AM and calcein red-777 
orange respectively, pooled in 1/1 ratio and injected in recipient mice. (B-D) 12h after 778 
injection, mice were sacrificed and biological samples were removed and analyzed to 779 
evaluate homing capacities of each cells . (B) Bone marrow of uninjected mice was used as 780 
control for staining specificity. (C) Dot plots of stained cells removed from blood, BM, 781 
spleen, liver and thymus. (D) Quantification and statistical analysis. Data are pooled from 3 782 
independent experiments or representative (for spleen panel). N=6 mice per group. All 783 
statistical significance was calculated by nonparametric Mann-Wihtney test. *p<0.05. 784 
**p<0.01.***p<0.001. 785 
 786 
Figure 7: Adhesion and migration assays (A). Adhesion assay on MS5 stromal cells. 787 
Percentage of adherent FL cells on MS5 stromal bone marrow cell line after 2 hours of 788 
incubation. Left panel: total FL cells. Right panel: LSK cells. Data are representative of 3 789 
independent experiments. Ptk-/- N=4; Ptk+/- N=6; Ptk+/+ N=3. (B to E) Migration in Boyden 790 
chamber assay. Number of migrating cells are normalized to the number of input cells for 791 
each sample (duplicate wells). (B) Migration of linNeg enriched FL cells without 792 
chemoattractant. (C) Migration of linNeg enrichied FL cells with SDF1a as chemoattracting 793 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r u
se
.
32 
 
reagent. (D). Migration of LSK FL cells without chemoattractant. (E). Migration of LSK 794 
FL cells with SDF1α as chemoattracting reagent. All statistical significance was calculated 795 
by nonparametric Mann-Wihtney test. *p<0.05. **p<0.01.***p<0.001.  796 
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